- Home
- HBM vs ACAD Comparison
HBM vs ACAD Comparison
Compare HBM & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBM
- ACAD
- Stock Information
- Founded
- HBM 1927
- ACAD 1993
- Country
- HBM Canada
- ACAD United States
- Employees
- HBM N/A
- ACAD N/A
- Industry
- HBM Metal Mining
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- HBM Basic Materials
- ACAD Health Care
- Exchange
- HBM Nasdaq
- ACAD Nasdaq
- Market Cap
- HBM 5.4B
- ACAD 4.3B
- IPO Year
- HBM N/A
- ACAD 2004
- Fundamental
- Price
- HBM $13.40
- ACAD $24.76
- Analyst Decision
- HBM
- ACAD Buy
- Analyst Count
- HBM 0
- ACAD 21
- Target Price
- HBM N/A
- ACAD $29.30
- AVG Volume (30 Days)
- HBM 5.0M
- ACAD 1.9M
- Earning Date
- HBM 11-12-2025
- ACAD 11-05-2025
- Dividend Yield
- HBM 0.11%
- ACAD N/A
- EPS Growth
- HBM 216.33
- ACAD 615.00
- EPS
- HBM 0.72
- ACAD 1.33
- Revenue
- HBM $2,202,000,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- HBM $13.79
- ACAD $14.01
- Revenue Next Year
- HBM N/A
- ACAD $12.00
- P/E Ratio
- HBM $18.54
- ACAD $18.54
- Revenue Growth
- HBM 8.31
- ACAD 14.41
- 52 Week Low
- HBM $5.95
- ACAD $13.40
- 52 Week High
- HBM $13.96
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- HBM 68.75
- ACAD 51.02
- Support Level
- HBM $11.62
- ACAD $23.34
- Resistance Level
- HBM $13.96
- ACAD $24.93
- Average True Range (ATR)
- HBM 0.34
- ACAD 0.83
- MACD
- HBM 0.02
- ACAD -0.18
- Stochastic Oscillator
- HBM 76.07
- ACAD 44.78
About HBM Hudbay Minerals Inc. (Canada)
Hudbay Minerals Inc is a Canadian mining company with its operations, property developments, and exploration activities across the United States. The mines that Hudbay operates are located in Manitoba, Canada, Arizona, United States; and Peru. The company is principally focused on the discovery, production, and marketing of base and precious metals. Hudbay produces copper concentrate, which contains copper, gold, and silver, as well as zinc metal. More than half the company's revenue is attributable to the copper business. The company sells copper concentrates to smelters across Asia, America, and Europe, and sells Zinc metal, another source of revenue, to industrial customers across North America.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.